A time-series analysis of the effect of increased copayments on the prescription of antidepressants, anxiolytics, and sedatives in Sweden from 1990 to 1999
- PMID: 12809972
- DOI: 10.1016/s0149-2918(03)80082-6
A time-series analysis of the effect of increased copayments on the prescription of antidepressants, anxiolytics, and sedatives in Sweden from 1990 to 1999
Abstract
Background: Outpatient prescription medication spending in Sweden has increased sharply since 1974. The Swedish government has raised copayments to reduce medication consumption and limit the growth of medication spending.
Objective: The aim of this study was to examine the effect of the 1995 and 1997 copayment increases on Swedish consumption of antidepressants, anxiolytics, sedatives.
Methods: Monthly drug-use data for July 1990 through December 1999 for these 3 pharmaceutical classes were obtained from Apoteket AB (Stockholm, Sweden). Data were provided for both sexes in units of defined daily doses per 1000 inhabitants. These series were analyzed with the use of Box-Jenkins autoregressive, integrated, moving-average time-series modeling methods.
Results: Dispensing of all 3 drugs classes increased immediately before copayment changes, with the exception of male sedative use at the time of the 1997 reform. Permanent increases in male antidepressant and sedative use occurred before the 1995 copayment reform. Only female antidepressant use was permanently reduced following the 1997 copayment reform.
Conclusions: Our findings suggest that Swedish patients' valuation of mental health medications exceeds the enacted price increases. The permanent increases in male antidepressant and sedative use, beginning in 1995, may have been the result of previous undertreatment. The permanent reduction in female antidepressant use, beginning in 1997, suggests that the price levels reached a threshold that matched or exceeded Swedish women's valuation of these modific
Similar articles
-
Trends in prescriptions and costs of drugs for mental disorders in England, 1998-2010.Br J Psychiatry. 2012 May;200(5):393-8. doi: 10.1192/bjp.bp.111.104257. Epub 2012 Mar 22. Br J Psychiatry. 2012. PMID: 22442100
-
Increase in the prescription rate of antidepressants after the Sewol Ferry disaster in Ansan, South Korea.J Affect Disord. 2017 Sep;219:31-36. doi: 10.1016/j.jad.2017.05.026. Epub 2017 May 10. J Affect Disord. 2017. PMID: 28505500 Free PMC article.
-
Prescription of anxiolytics, sedatives, hypnotics and antidepressants in outpatient, universal care during the COVID-19 pandemic in Portugal: a nationwide, interrupted time-series approach.J Epidemiol Community Health. 2022 Apr;76(4):335-340. doi: 10.1136/jech-2021-216732. Epub 2021 Oct 8. J Epidemiol Community Health. 2022. PMID: 34625519
-
Cost savings with nefazodone in treating depression.J Clin Psychiatry. 2002;63 Suppl 1:48-51. J Clin Psychiatry. 2002. PMID: 11890565 Review.
-
Utilization of antidepressants, anxiolytics, and hypnotics during the COVID-19 pandemic.Transl Psychiatry. 2024 Apr 4;14(1):175. doi: 10.1038/s41398-024-02894-z. Transl Psychiatry. 2024. PMID: 38575574 Free PMC article. Review.
Cited by
-
The effect of pharmaceutical co-payment increase on the use of social assistance-A natural experiment study.PLoS One. 2021 May 5;16(5):e0250305. doi: 10.1371/journal.pone.0250305. eCollection 2021. PLoS One. 2021. PMID: 33951077 Free PMC article.
-
Effect of the economic recession on pharmaceutical policy and medicine sales in eight European countries.Bull World Health Organ. 2014 Sep 1;92(9):630-640D. doi: 10.2471/BLT.13.129114. Epub 2014 Jun 16. Bull World Health Organ. 2014. PMID: 25378754 Free PMC article.
-
[Prescription drug consumption recovery following the co-payment change: Evidence from a regional health service].Aten Primaria. 2015 Aug-Sep;47(7):411-8. doi: 10.1016/j.aprim.2014.10.005. Epub 2014 Dec 11. Aten Primaria. 2015. PMID: 25500171 Free PMC article. Spanish.
-
Medicare Part D benzodiazepine exclusion and use of psychotropic medication by patients with new anxiety disorders.Psychiatr Serv. 2012 Jul;63(7):637-42. doi: 10.1176/appi.ps.201100331. Psychiatr Serv. 2012. PMID: 22549332 Free PMC article.
-
Reforming the Swedish pharmaceuticals market: consequences for costs per defined daily dose.Int J Health Econ Manag. 2016 Sep;16(3):201-214. doi: 10.1007/s10754-016-9186-4. Epub 2016 Feb 8. Int J Health Econ Manag. 2016. PMID: 27878673
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical